Non-Small Cell Lung Cancer (NSCLC)

Latest News

Patritumab deruxtecan continues to yield positive efficacy in 2 early phase trials assessing the agent in patients with metastatic non–small cell lung cancer and breast cancer.
Patritumab Deruxtecan Demonstrates Continued Activity in Breast/Lung Cancer

March 22nd 2023

Patritumab deruxtecan continues to yield positive efficacy in 2 early phase trials assessing the agent in patients with metastatic non–small cell lung cancer and breast cancer.

New findings from the phase 3 ADAURA trial “provide powerful evidence” of osimertinib’s potential to extend the lives of patients with early-stage, EGFR-mutant non–small cell lung cancer, according to an expert from Yale Cancer Center.
Adjuvant Osimertinib Appears to Extend Overall Survival in EGFR+ NSCLC

March 18th 2023

Final analyses for pathologic response appear consistent with previous reports from the phase 3 AEGEAN trial evaluating neoadjuvant durvalumab and chemotherapy plus adjuvant durvalumab monotherapy in resectable non–small cell lung cancer.
Neoadjuvant/Adjuvant Durvalumab Yields Meaningful EFS Benefit in NSCLC

March 9th 2023

The VENTANA PD-L1 Assay becomes the only FDA-approved companion diagnostic with locally advanced or metastatic non–small cell lung cancer indications for 4 immunotherapy agents.
FDA Expands VENTANA PD-L1 Assay Label for Cemiplimab in NSCLC Subtype

March 6th 2023

Investigators report that pembrolizumab plus enzalutamide and androgen deprivation therapy does not significantly improve outcomes in castration-resistant prostate cancer; neither did pembrolizumab/chemotherapy in non–small cell lung cancer.
Two Phase 3 Pembrolizumab Trials Show Lack of Benefit in Prostate/Lung Cancer

March 5th 2023

More News